In the present investigation we studied serum anti-thyroglobulin and anti-thyroid microsomal
autoantibodies, measured by hemagglutination technique, in 600 patients with thyroid …

Thyroid carcinoma is rare among human malignancies (! 1%) but is the most frequent
endocrine cancer, accounting for about 5% of thyroid nodules (1). The latter are very frequent in …

Background Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2,
and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α…

Background Patients with radioactive iodine ( 131 I)-refractory locally advanced or metastatic
differentiated thyroid cancer have a poor prognosis because of the absence of effective …

Purpose Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET),
vascular endothelial growth factor receptor 2, and rearranged during transfection (…

Purpose There is no effective therapy for patients with advanced medullary thyroid carcinoma
(MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth …

Importance BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its
role in PTC-related patient mortality has not been established. Objective To investigate the …

The survival rate of patients with medullary thyroid carcinoma (MTC) is significantly better in
patients diagnosed and treated when the tumor is limited to the thyroid. In a pioneer study …

Background: The BRAF V600E mutation is the most frequent genetic alteration in papillary
thyroid carcinoma (PTC). The role of BRAF V600E mutation as a poor prognostic factor has …

Background Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in
advanced RET-mutant medullary thyroid cancer in a phase 1–2 trial, but its efficacy as …